Thyrocare Technologies LimitedQ2FY27 Results & Financial Update
Thyrocare Technologies Limited: Q2FY27 consolidated results and company financials – revenue ₹270.81 Cr, PAT ₹15.22 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceReported figures and period changes.Changes compare like-for-like reported periods where available.
Find an answer
Ask this result
Chart · Market context
Thyrocare Technologies price & chart
Market price₹514.45
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Thyrocare Technologies Q2FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Thyrocare Technologies Limited reported a consolidated revenue from operations of INR 270.81 crore for Q2FY27, marking a 25.1% increase compared to INR 216.53 crore in the corresponding quarter of the previous year. Growth was propelled primarily by strong momentum in the Pathology segment.
Consolidated EBITDA reached INR 89.3 crore, representing a 24.9% growth year-on-year from INR 71.5 crore, supported by operational efficiencies and scale. Profit After Tax (PAT) before exceptional items grew 25.7% year-on-year to INR 60.2 crore.
Reported PAT stood at INR 15.22 crore, impacted by a one-time, non-cash impairment charge of INR 45.0 crore recognized in connection with a definitive term sheet for the proposed divestment of its Nuclear Healthcare (NHL) radiology business. Management noted that this impairment is transaction-specific and does not affect core operational performance.
The Pathology segment continued its robust expansion, registering a 26.7% year-on-year increase in revenue to INR 256.3 crore. Franchise revenue within pathology advanced 26.9% year-on-year, while partnership revenue grew 27.9% year-on-year.
Volume metrics underscored leadership in test processing, with the company handling 61.6 million tests during Q2FY27, up 27.4% year-on-year. Active quarterly franchisees expanded significantly by approximately 1,180 additions during the quarter to reach 12,911.
Quality metrics remained a focal point, with complaints per million tests declining 24% year-on-year to 2.90, alongside an average turnaround time (ATAT) from sample receipt of 3.49 hours.
Strategic initiatives during the quarter included an expansion into specialty diagnostics—such as allergy testing and genomics via the launch of NIPT—and the introduction of India's first rapid pregnancy test kit bundled with a confirmatory lab test, distributed across more than 10,000 chemists.
01 · Business model
What does Thyrocare Technologies do?
Thyrocare Technologies Limited operates as a leading fully automated healthcare diagnostics company in India, offering comprehensive pathology and radiology testing services. Founded in 1996, the company focuses on delivering affordable diagnostic solutions through a vast laboratory network and standardized processes.
The operational footprint spans a pan-India network of 49 laboratories, which includes 2 Central Processing Labs, 2 Zonal Processing Labs, 26 Regional Processing Labs, 6 Satellite Processing Labs, 8 Hybrid Labs, 4 Acquired Labs, and 1 international laboratory located in Tanzania.
Thyrocare distributes its services primarily through B2B channels consisting of franchise collection centers (representing 62% of pathology revenue) and institutional partnerships with online diagnostic aggregators, healthcare platforms, and wellness providers (representing 33% of pathology revenue), alongside a direct-to-consumer channel.
The company's test menu comprises over 1,420 comprehensive test offerings, processing millions of diagnostic investigations while maintaining quality accreditations including NABL and CAP.
02 · Historical context
What shaped the business before this quarter
Thyrocare obtained ISO 9001:2000 certification in 2001 (later upgraded to ISO 9001:2015) and NABL and CAP accreditations in 2005.
03 · Financial snapshot
Current quarter vs the two useful baselines
| Metric | Q2FY27 | Year-ago | Previous quarter |
|---|---|---|---|
| Revenue from operations | ₹270.81 Cr | ₹216.53 Cr | ₹240.02 Cr |
| Total income | ₹274.44 Cr | ₹219.58 Cr | — |
| Profit before tax | ₹33.65 Cr | ₹62.58 Cr | ₹67.58 Cr |
| Profit after tax | ₹15.22 Cr | ₹47.81 Cr | ₹51.33 Cr |
| EPS | ₹0.96 | ₹3.00 | ₹3.23 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Pathology revenue grew by 26.7% year-on-year to INR 256.3 crore, driven by robust volume growth and wider network penetration.
Franchise revenue increased by 26.9% year-on-year to INR 159.2 crore, and partnership revenue grew by 27.9% year-on-year to INR 83.9 crore.
Total tests conducted rose 27.4% year-on-year to 61.6 million, while total patients served reached 5.7 million, up 13.4% year-on-year.
What drove margins
Consolidated gross margin improved by 190 basis points year-on-year to 74.2%, supported by operating leverage and scale efficiencies.
Employee benefit expenses increased year-on-year to INR 45.2 crore, reflecting ongoing expansion across laboratory facilities and specialty diagnostics teams.
Other expenses rose to INR 66.5 crore, driven by promotional outlays for the newly launched pregnancy test kit and brand ambassador fees.
05 · Demand, customers & order book
Where demand is coming from
Quarterly active franchisees reached 12,911, achieving the highest quarterly addition of approximately 1,180 franchisees in three years.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Pathology operations represented the core of the business, generating INR 256.3 crore in revenue with an EBITDA margin of 33.6% on a standalone basis.
Radiology revenue (comprising Nuclear healthcare and Pulse Hi-tech businesses) stood at INR 13.6 crore, down 4.2% year-on-year due to strategic exits from non-profitable centers.
Geography and market mix
The laboratory network reached 49 locations across India, with regional pathology revenue distribution standing at 29% West, 26% South, 24% North, and 21% East.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The company launched 4 new Regional Processing Laboratories (Asansol, Nasik, Madurai, Jabalpur) and 1 hybrid lab in Jamshedpur during Q2FY27 to strengthen turnaround times.
Projects, capex and execution
H1FY27 cash flow from investing activities reflects capital expenditure of INR 33.2 crore directed toward 8 new lab expansions and machine additions for capacity.
08 · Strategy & new businesses
How the company is trying to change its growth mix
Thyrocare advanced its 'From Routine to Remarkable' strategy by scaling specialty testing in allergy and genomics, including the launch of NIPT.
The company launched India's first rapid pregnancy test kit bundled with a confirmatory lab test, onboarding actress Yami Gautam as brand ambassador and reaching over 10,000 chemists via API Holdings group company Ascent.
09 · Reported developments
What changed operationally
Thyrocare entered into a definitive term sheet for the proposed divestment of 100% of its Nuclear Healthcare (NHL) business for a total consideration of INR 141.4 crore (comprising INR 81.9 crore in cash and INR 59.5 crore in Trovera CCPS), allowing management to focus capital on the higher-ROCE pathology business.
10 · Pressure points & risks
What is not going smoothly
Recognized a one-time, non-cash impairment charge of INR 45.0 crore at the consolidated level in connection with the proposed sale of the NHL business.
11 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Net cash flow generated from operating activities for H1FY27 stood at INR 132.8 crore, compared to INR 127.1 crore in H1FY26.
Financing cash outflows for H1FY27 included a dividend payout of INR 111.4 crore to shareholders.
Capital allocation & funding
The company maintained a debt-free status with no external borrowings; reported finance costs of INR 1.6 crore for the quarter are primarily attributable to Ind AS lease accounting adjustments.
12 · Beyond the numbers
What changed beyond the numbers
Reported update
Brand Ambassador Partnership
Onboarded actress Yami Gautam as brand ambassador for the newly launched Pregnancy Test Kit to drive consumer awareness across chemist outlets.
13 · Previous-quarter changes
What changed since the previous quarter
Consolidated revenue expanded sequentially from INR 240.0 crore in Q1FY27 to INR 270.81 crore in Q2FY27.
14 · Key Q&A
The quarter, answered directly
What does Thyrocare Technologies do?
Thyrocare Technologies Limited operates as a leading fully automated healthcare diagnostics company in India, offering comprehensive pathology and radiology testing services. Founded in 1996, the company focuses on delivering affordable diagnostic solutions through a vast laboratory network and standardized processes.
What is the clearest takeaway from Q2FY27?
Thyrocare Technologies Limited reported a consolidated revenue from operations of INR 270.81 crore for Q2FY27, marking a 25.1% increase compared to INR 216.53 crore in the corresponding quarter of the previous year. Growth was propelled primarily by strong momentum in the Pathology segment.
What drove revenue or demand?
Pathology revenue grew by 26.7% year-on-year to INR 256.3 crore, driven by robust volume growth and wider network penetration.
What mattered most for margins or profitability?
Consolidated gross margin improved by 190 basis points year-on-year to 74.2%, supported by operating leverage and scale efficiencies.
What changed operationally beyond the headline numbers?
The company launched 4 new Regional Processing Laboratories (Asansol, Nasik, Madurai, Jabalpur) and 1 hybrid lab in Jamshedpur during Q2FY27 to strengthen turnaround times.
What are the main pressure points disclosed for the quarter?
Recognized a one-time, non-cash impairment charge of INR 45.0 crore at the consolidated level in connection with the proposed sale of the NHL business.
15 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
16 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Shareholder Approval for NHL Divestment: Monitor the outcome of the postal ballot seeking shareholder approval for the divestment of the Nuclear Healthcare business.
- 02
Specialty Portfolio Scaling: Track the commercial traction and revenue contribution from newly introduced specialty test menus such as allergy and genomics (NIPT).
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.